Ventripoint Diagnostics Ltd. (TSX-V:VPT, OTC:VPTDF) announced that its strategic partner, Lishman Global Inc., has formally submitted the VMS+™ 4.0 system to China’s National Medical Products Administration (NMPA) for regulatory approval. Lishman Global has qualified for the NMPA’s “green channel” pathway, an expedited review process designed to accelerate approval of innovative medical technologies addressing significant clinical needs. This designation is expected to streamline the regulatory timeline and facilitate faster access to the Chinese market.
This submission represents a significant milestone in Ventripoint’s global expansion strategy, reflecting growing demand for advanced, accessible cardiac imaging solutions in one of the world’s largest healthcare markets. Cardiovascular disease remains the leading cause of mortality in China, with an estimated 330 million patients affected. Echocardiography is the most widely used cardiac imaging modality due to its cost-effectiveness, portability, and scalability across urban and rural settings. However, variability in image interpretation and limited access to advanced modalities like MRI have created a strong need for AI-driven tools that improve diagnostic accuracy and workflow efficiency.
Ventripoint’s VMS+™ 4.0 addresses this need by providing MRI-equivalent volumetric measurements using standard 2D echocardiography. Powered by the Company’s proprietary Knowledge Based Reconstruction technology, the platform enables clinicians to assess all four chambers of the heart with high accuracy, supporting diagnosis and management of conditions such as congenital heart defects, heart failure, pulmonary hypertension, cardiotoxicity, and valvular disease.
“We are excited to take this important step toward bringing VMS+™ 4.0 to the Chinese market,” said Paul Gibson, Chief Technology Officer of Lishman Global Inc. “Qualification for the NMPA’s green channel underscores the clinical relevance and innovation of VMS+™ 4.0 and provides a clear pathway to accelerated adoption. China’s scale, combined with its increasing focus on improving cardiovascular outcomes, makes it an ideal environment for this technology.”
“Hitting this regulatory milestone with Lishman Global is a key validation of both our technology and our international strategy,” said Hugh MacNaught, President and Chief Executive Officer of Ventripoint Diagnostics. “China is one of the most important cardiac care markets in the world. With the benefit of an expedited review pathway, we are well positioned to bring VMS+™ 4.0 to clinicians and patients more quickly. By enabling more accurate and reproducible cardiac measurements using existing ultrasound infrastructure, VMS+ has the potential to significantly expand access to high-quality cardiac care.”
The green channel designation is particularly significant because it signals that NMPA recognizes the technology’s potential to address unmet medical needs. For Ventripoint, this could mean faster market entry and a competitive advantage in a country where cardiovascular disease is a major public health challenge. The ability to use existing ultrasound machines to obtain MRI-quality measurements could democratize access to advanced cardiac diagnostics, especially in rural areas where MRI is scarce.
The Company will provide further updates as the regulatory review process progresses. More information about Ventripoint and its VMS+ technology can be found on SEDAR and the original release on NewMediaWire.
